IPSEN Total Non-Operating Income/Expense 2016-2024 | IPSEY

IPSEN total non-operating income/expense for the twelve months ending December 31, 2024 was $0M, a 0% increase year-over-year.

  • IPSEN annual total non-operating income/expense for 2024 was $-0.07B, a 19.25% increase from 2023.
  • IPSEN annual total non-operating income/expense for 2023 was $-0.059B, a 133.27% increase from 2022.
  • IPSEN annual total non-operating income/expense for 2022 was $-0.025B, a 38.76% decline from 2021.

IPSEN Total Non-Operating Income/Expense 2016-2024 | IPSEY

  • IPSEN annual total non-operating income/expense for 2024 was $-0.07B, a 19.25% increase from 2023.
  • IPSEN annual total non-operating income/expense for 2023 was $-0.059B, a 133.27% increase from 2022.
  • IPSEN annual total non-operating income/expense for 2022 was $-0.025B, a 38.76% decline from 2021.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$76.6B
Zoetis (ZTS)$69B
Takeda Pharmaceutical (TAK)$46.7B
Daiichi Sankyo, - (DSNKY)$41.7B
BeOne Medicines - (ONC)$27.4B
Sandoz Group AG (SDZNY)$24.6B
Summit Therapeutics (SMMT)$18.6B
Merck (MKKGY)$17.2B
Shionogi (SGIOY)$14.2B
United Therapeutics (UTHR)$13.3B
Neurocrine Biosciences (NBIX)$13.2B
Orion OYJ (ORINY)$11B
Stevanato Group S.p.A (STVN)$7.6B
Corcept Therapeutics (CORT)$7.6B
Madrigal Pharmaceuticals (MDGL)$7B
Grifols, S.A (GRFS)$6.7B
Ionis Pharmaceuticals (IONS)$6.6B
Hikma Pharmaceuticals Plc (HKMPF)$6.2B
Ono Pharmaceutical (OPHLF)$5.1B
Soleno Therapeutics (SLNO)$4.1B
Crinetics Pharmaceuticals (CRNX)$3B
Hypermarcas (HYPMY)$3B
Catalyst Pharmaceuticals (CPRX)$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
NewAmsterdam Pharma (NAMS)$2.4B
Centessa Pharmaceuticals (CNTA)$1.9B
BioCryst Pharmaceuticals (BCRX)$1.8B
Ocular Therapeutix (OCUL)$1.8B
ARS Pharmaceuticals (SPRY)$1.7B
Endo (NDOI)$1.6B